-
-
-
-
-
-
-
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
-
-
-
-
-
-
-
SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors
-
-
-
-
-
-
-
Form S-1/A SpringWorks Therapeutics
51,662 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All